These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22494652)

  • 21. Translational genomics in breast cancer.
    Caldas C
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S381-2. PubMed ID: 21944024
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of new molecules in the treatment of advanced thyroid cancer].
    Galofré JC; Gómez-Sáez JM; Álvarez Escola C; Álvarez García E; Anda Apiñaniz E; Calleja A; Donnay S; Lucas-Martin A; Menéndez Torre E; Navarro González E; Pereg V; Pérez Corral B; Santamaría Sandi J; Riesco Eizaguirre G; Zafón Llopis C;
    Endocrinol Nutr; 2011 Oct; 58(8):381-6. PubMed ID: 21924966
    [No Abstract]   [Full Text] [Related]  

  • 23. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valuing end-of-life care in the United States: the case of new cancer drugs.
    Sorenson C
    Health Econ Policy Law; 2012 Oct; 7(4):411-30. PubMed ID: 23079300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can genomics bend the cost curve?
    Armstrong K
    JAMA; 2012 Mar; 307(10):1031-2. PubMed ID: 22416096
    [No Abstract]   [Full Text] [Related]  

  • 29. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.
    Hsu JC; Lu CY
    BMJ Open; 2016 Jun; 6(6):e011322. PubMed ID: 27266775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost of cancer care: issues and implications.
    Meropol NJ; Schulman KA
    J Clin Oncol; 2007 Jan; 25(2):180-6. PubMed ID: 17210937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
    Meyers FJ; Linder J; Beckett L; Christensen S; Blais J; Gandara DR
    J Pain Symptom Manage; 2004 Dec; 28(6):548-56. PubMed ID: 15589080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009.
    Savage P
    J Oncol Pharm Pract; 2012 Mar; 18(1):52-6. PubMed ID: 21109615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecule based diagnosis].
    Akaza H; Ichikawa T; Tsuruo T; Shimada Y; Moriwaki H; Mori M; Noguchi S; Nakamura S; Saijo N; Sone S; Isonishi S; Ohashi Y; Hinotsu S; von Euler M; Blackedge G
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):125-33. PubMed ID: 14750337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast disease.
    Johnston SR
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S4-5. PubMed ID: 21944027
    [No Abstract]   [Full Text] [Related]  

  • 37. Allocating cancer-directed expenditures: tensions between prevention, early detection and treatment is unnecessary.
    Hillner BE; Smith TJ
    Recent Results Cancer Res; 2011; 188():1-9. PubMed ID: 21253785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-negative breast cancer.
    Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
    Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines.
    Anderson BO; Shyyan R; Eniu A; Smith RA; Yip CH; Bese NS; Chow LW; Masood S; Ramsey SD; Carlson RW
    Breast J; 2006; 12 Suppl 1():S3-15. PubMed ID: 16430397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
    Parkinson DR; Johnson BE; Sledge GW
    Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.